CLTI Defined as Rutherford Category 4 or 5

1

Review clinical trials related to CLTI Defined as Rutherford Category 4 or 5. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization

Chronic limb threatening ischemia (CLTI) is defined as ischemic foot pain at rest or non-healing foot wounds that is attributable to severe peripheral arterial disease (PAD).Revascularization is the cornerstone of therapy to relieve ischemic pain, prevent limb loss and preserve patient autonomy. Revascularization procedures often involve below-the-knee arterial disease in CLTI population. Dual antiplatelet therapy (DAPT, with aspirin, and clopidogrel) is recommended for at least 1-month after peripheral angioplasty. However, the exact duration of this DAPT remains controversial. Angioplasty of below-the-knee arteries is often followed by a longer period of DAPT, 3-months to one-year, due to a high risk of arterial thrombosis/stenosis.It will be the first trial on duration of DAPT in patients with below-the-knee angioplasty for CLTI, the end-stage of PAD

Participants needed: 614
Trial details
Phase: Phase 3Age: 18-99Biological sex: AllType: InterventionalSponsor: Fondation Hôpital Saint-JosephUpdated: Jun 24, 2026Locations: 1
Eligibility criteria

Age ≥18 years [+5]

PAD Rutherford category 0, 1, 2, 3 or 6 (Rutherford 6 defined as severe [+20]